Shares of Calithera Biosciences Inc. (NASDAQ:CALA) fell 5.2% during mid-day trading on Tuesday . The stock traded as low as $3.10 and last traded at $3.11, with a volume of 72,055 shares. The stock had previously closed at $3.28.

Several brokerages have recently issued reports on CALA. JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a report on Wednesday, June 8th. Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a report on Tuesday, May 17th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Calithera Biosciences in a report on Thursday, May 12th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $10.38.

The firm’s 50 day moving average is $3.37 and its 200-day moving average is $4.82. The company’s market cap is $59.52 million.

Calithera Biosciences (NASDAQ:CALA) last issued its quarterly earnings data on Tuesday, August 9th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.52) by $0.03. Equities research analysts forecast that Calithera Biosciences Inc. will post ($2.16) earnings per share for the current fiscal year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.